Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tenofovir Disoproxil Fumarate Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).

NCT01769469
View directory record Official record
Conditions
HIV Infection
Interventions
FTC/TDF (Truvada®)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 22 Years · Male only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

NCT00507689
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
FTC/TDF, Hepatitis B Immunoglobulin (HBIg)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01797445
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

NCT00298363
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Tenofovir disoproxil fumarate (tenofovir DF; TDF), Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Entecavir (ETV), TDF placebo, FTC/TDF placebo, ETV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 7, 2026, 5:18 AM EDT
Completed No phase listed Observational

Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism

NCT01361165
View directory record Official record
Conditions
HIV-Infected Children
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 7, 2026, 5:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study

NCT07462611
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis, PrEP
Interventions
PrEP Uptake with Rapid Start, Pre-Exposure Prophylaxis (PrEP) Persistence
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents

NCT01721109
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
EVG/COBI/FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Oakland, California • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

NCT01943799
View directory record Official record
Conditions
Chronic HBV Infection
Interventions
GS-4774, OAV Regimen
Biological · Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 1 Interventional Results available

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

NCT03976752
View directory record Official record
Conditions
HIV/AIDS
Interventions
Genvoya
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 7, 2026, 5:18 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

ANCHORS Alcohol & Sexual Health Study: UH3 Project

NCT04331704
View directory record Official record
Conditions
Alcohol Use, Unspecified, Substance Use, Sex Behavior
Interventions
PrEP acronym (pre-exposure prophylaxis), Initial Web Survey, Interactive Voice Response (IVR) monitoring, Educational material on alcohol and sexual health behavior, Interactive Voice Response (IVR) assessment with personalized information, Personalized information based on web-based survey responses & standardized information
Drug · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 7, 2026, 5:18 AM EDT
Not yet recruiting Phase 1 Interventional

Repurposing a Combination Antiretroviral Drug Therapy to Target Retrotransposons and Treat Early Alzheimer's Disease

NCT07795307
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Emtricitabine and tenofovir disoproxil fumarate combination, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

NCT00507507
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Tenofovir DF, FTC, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots

NCT02022657
View directory record Official record
Conditions
PrEP Adherence Monitoring
Interventions
Truvada
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Francisco, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 7, 2026, 5:18 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Botswana Tenofovir Oral HIV Prophylaxis Trial

NCT00111150
View directory record Official record
Conditions
HIV Infection
Interventions
Tenofovir Disoproxil Fumarate 300 mg daily
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 29 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2007 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

NCT02605954
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

NCT01903031
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Nuvaring, EFV, ATV/r, TDF, NRTIs
Device · Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 4 Interventional Results available

Parrying the Pitfalls of PrEP: Project PEACH

NCT05072093
View directory record Official record
Conditions
HIV, STI
Interventions
PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP, Injectable PrEP
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 7, 2026, 5:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Factors Affecting PrEP Adherence

NCT02411630
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 22 Years · Male only
Enrollment
167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

NCT03197961
View directory record Official record
Conditions
HIV/AIDS, Contraception
Interventions
tenofovir/emtricitabine, DMPA
Combination Product · Drug
Lead sponsor
Sharon Achilles
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 7, 2026, 5:18 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 7, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional Results available

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

NCT06005610
View directory record Official record
Conditions
HIV I Infection
Interventions
Estradiol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women

NCT03270969
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir Disoproxil Fumarate/Emtricitabine
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

NCT01338883
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 7, 2026, 5:18 AM EDT